BioCentury
ARTICLE | Clinical News

BTA585: Phase I started

September 21, 2015 7:00 AM UTC

Biota began a placebo-controlled, dose-escalation Phase I trial to evaluate 5 single doses of 50-500 mg oral BTA585 in about 50 healthy volunteers. Next quarter, the company plans to start a Phase I t...